PMID- 12553375
OWN - NLM
STAT- MEDLINE
DCOM- 20030212
LR  - 20191025
IS  - 0262-0898 (Print)
IS  - 0262-0898 (Linking)
VI  - 19
IP  - 8
DP  - 2002
TI  - EMMPRIN-mediated MMP regulation in tumor and endothelial cells.
PG  - 697-702
AB  - Tumor invasion and metastasis are multistep processes which require extracellular 
      matrix remodeling by proteolytic enzymes such as matrix metalloproteinases 
      (MMPs). The production of these enzymes is stimulated by many soluble or 
      cell-bound factors. Among these factors, extracellular matrix metalloproteinase 
      inducer (EMMPRIN) is known to increase in vitro stromal cell production of MMP-1, 
      MMP-2 and MMP-3. In this study, we demonstrated that EMMPRIN-transfected 
      MDA-MB-436 tumor cells displayed a more invasive capacity than vector-transfected 
      cells in a modified Boyden chamber invasion assay. Using gelatin zymography and 
      protein analyses, we showed that EMMPRIN-transfected cancer cells produced 
      significantly more latent and active MMP-2 and MMP-3 than vector-transfected 
      cancer cells. We found that EMMPRIN did not regulate MMP-1, MMP-9, membrane 
      type-1 MMP (MT1-MMP) expression and had also no effect on the production of the 
      specific tissue inhibitors of MMPs (TIMPs), TIMP-1 and TIMP-2. We also 
      demonstrated that tumor-derived EMMPRIN stimulated MMP-1, -2, and -3 without 
      modification of MMP-9, MT1-MMP, TIMP-1 and TIMP-2 production in human umbilical 
      vein endothelial cells (HUVEC). These data provide support for the role of 
      EMMPRIN in tumor invasion, metastasis, and neoangiogenesis by stimulating 
      extracellular matrix remodeling around tumor cell clusters, stroma, and blood 
      vessels.
FAU - Caudroy, Stephanie
AU  - Caudroy S
AD  - Inserm U514, IFR53, CHU Maison-Blanche, Reims, France.
FAU - Polette, Myriam
AU  - Polette M
FAU - Nawrocki-Raby, Beatrice
AU  - Nawrocki-Raby B
FAU - Cao, Jian
AU  - Cao J
FAU - Toole, Bryan P
AU  - Toole BP
FAU - Zucker, Stanley
AU  - Zucker S
FAU - Birembaut, Philippe
AU  - Birembaut P
LA  - eng
GR  - R01-CA79866/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (BSG protein, human)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Culture Media, Serum-Free)
RN  - 0 (DNA, Complementary)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 136894-56-9 (Basigin)
RN  - 9000-70-8 (Gelatin)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - *Antigens, CD
MH  - Antigens, Neoplasm/physiology
MH  - Basigin
MH  - Breast Neoplasms/blood supply/*pathology
MH  - Culture Media, Conditioned
MH  - Culture Media, Serum-Free
MH  - DNA, Complementary
MH  - Endothelium, Vascular/*enzymology
MH  - Gelatin/metabolism
MH  - Humans
MH  - Matrix Metalloproteinases/*metabolism
MH  - Membrane Glycoproteins/genetics/*metabolism
MH  - Neoplasm Invasiveness
MH  - Recombinant Fusion Proteins/metabolism
MH  - Transfection
MH  - Tumor Cells, Cultured
EDAT- 2003/01/30 04:00
MHDA- 2003/02/14 04:00
CRDT- 2003/01/30 04:00
PHST- 2003/01/30 04:00 [pubmed]
PHST- 2003/02/14 04:00 [medline]
PHST- 2003/01/30 04:00 [entrez]
AID - 10.1023/a:1021350718226 [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 2002;19(8):697-702. doi: 10.1023/a:1021350718226.